Drug Resistance in Anaplastic Lymphoma Kinase-rearranged Lung Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Jan 17

PMID 29336091

Citations 29

Authors

Ryohei Katayama

Affiliations

Soon will be listed here.

Abstract

The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, and many kinds of ALK fusion genes have been found in a variety of carcinomas. There is almost no detectable expression of ALK in adults. However, through ALK gene rearrangement, the resultant ALK fusion protein is aberrantly overexpressed and dimerized through the oligomerization domains, such as the coiled-coil domain, in the fusion partner that induces abnormal constitutive activation of ALK tyrosine kinase. This results in dysregulated cell proliferation. ALK gene rearrangement has been observed in 3%-5% of non-small-cell lung cancers, and multiple ALK inhibitors have been developed for the treatment of ALK-positive lung cancer. Among those inhibitors, in Japan, 3 (4 in the USA) ALK tyrosine kinase inhibitors (TKIs) have been approved and are currently used in clinics. All of the currently approved ALK-TKIs have been shown to induce marked tumor regression in ALK-rearranged non-small-cell lung cancer; however, tumors inevitably relapse because of acquired resistance within a few years. This review focuses on ALK-TKIs, their resistance mechanisms, and the potential therapeutic strategies to overcome resistance.

Citing Articles

Chromatographic analysis of ponatinib and its impurities: method development, validation, and identification of new degradation product.

Wang J, Zhu Y, Qin J, Wu W, Huang R, Cai L Front Chem. 2024; 12:1487108.

PMID: 39600314 PMC: 11588477. DOI: 10.3389/fchem.2024.1487108.

ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report.

Chen R, Jian Y, Liu Y, Xie J Front Oncol. 2024; 14:1395654.

PMID: 38720809 PMC: 11078020. DOI: 10.3389/fonc.2024.1395654.

LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.

Mori S, Izumi H, Araki M, Liu J, Tanaka Y, Kagawa Y Commun Biol. 2024; 7(1):412.

PMID: 38575808 PMC: 10995188. DOI: 10.1038/s42003-024-06116-6.

Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine.

Salmani-Javan E, Farhoudi Sefidan Jadid M, Zarghami N Iran J Basic Med Sci. 2024; 27(2):122-133.

PMID: 38234663 PMC: 10790298. DOI: 10.22038/IJBMS.2023.72407.15749.

PROTACs: A novel strategy for cancer drug discovery and development.

Han X, Sun Y MedComm (2020). 2023; 4(3):e290.

PMID: 37261210 PMC: 10227178. DOI: 10.1002/mco2.290.

References

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L . P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2016; 3:54-66. PMC: 4739423. DOI: 10.1016/j.ebiom.2015.12.009. View

Mathew P, Morris S, Kane J, Shurtleff S, Pasquini M, Jenkins N . Localization of the murine homolog of the anaplastic lymphoma kinase (AlK) gene on mouse chromosome 17. Cytogenet Cell Genet. 1995; 70(1-2):143-4. DOI: 10.1159/000134080. View

Friboulet L, Li N, Katayama R, Lee C, Gainor J, Crystal A . The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014; 4(6):662-673. PMC: 4068971. DOI: 10.1158/2159-8290.CD-13-0846. View

Anai S, Takeshita M, Ando N, Ikematsu Y, Mishima S, Ishida K . A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK. J Thorac Oncol. 2016; 11(10):e126-8. DOI: 10.1016/j.jtho.2016.07.008. View

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely C . RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015; 21(9):1038-47. PMC: 4734742. DOI: 10.1038/nm.3930. View

Stoica G, Kuo A, Powers C, Bowden E, Sale E, Riegel A . Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002; 277(39):35990-8. DOI: 10.1074/jbc.M205749200. View

Murray P, Lax I, Reshetnyak A, Ligon G, Lillquist J, Natoli Jr E . Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal. 2015; 8(360):ra6. DOI: 10.1126/scisignal.2005916. View

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S . RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3):378-81. DOI: 10.1038/nm.2658. View

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

10.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

11.

Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K . FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. Elife. 2015; 4:e09811. PMC: 4658194. DOI: 10.7554/eLife.09811. View

12.

Lovly C, Pao W . Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med. 2012; 4(120):120ps2. DOI: 10.1126/scitranslmed.3003728. View

13.

Reshetnyak A, Murray P, Shi X, Mo E, Mohanty J, Tome F . Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci U S A. 2015; 112(52):15862-7. PMC: 4702955. DOI: 10.1073/pnas.1520099112. View

14.

Shaw A, Kim D, Mehra R, Tan D, Felip E, Chow L . Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(13):1189-97. PMC: 4079055. DOI: 10.1056/NEJMoa1311107. View

15.

Tang S, Nguyen L, Sparidans R, Wagenaar E, Beijnen J, Schinkel A . Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2013; 134(6):1484-94. DOI: 10.1002/ijc.28475. View

16.

Chen Y, Takita J, Choi Y, Kato M, Ohira M, Sanada M . Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008; 455(7215):971-4. DOI: 10.1038/nature07399. View

17.

Stoica G, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C . Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001; 276(20):16772-9. DOI: 10.1074/jbc.M010660200. View

18.

Lim S, Kim H, Lee J, Lee K, Lee Y, Min Y . Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017; 35(23):2613-2618. DOI: 10.1200/JCO.2016.71.3701. View

19.

Gainor J, Sherman C, Willoughby K, Logan J, Kennedy E, Brastianos P . Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2014; 10(2):232-6. PMC: 4304931. DOI: 10.1097/JTO.0000000000000455. View

20.

Bilsland J, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters K . Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology. 2007; 33(3):685-700. DOI: 10.1038/sj.npp.1301446. View